← All trials
NCT03431558
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2018
- Primary completion
- Apr 30, 2019
- Completion date
- Apr 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 300
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Aga Khan UniversityLead sponsor
- United States Agency for International DevelopmentCollaborator
- Aga Khan UniversityReponsible party - principal investigator
- Aga Khan UniversityOverall official - principal investigator
- Aga Khan UniversityStudy director
- University of SydneyStudy chair
- University of SydneyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.